Selection of patients for sublingual versus subcutaneous immunotherapy

Immunotherapy

Volumn 6, Issue 7, 2014, Pages 871-884

  Linnemann, Désirée E S Larenas ^a   Blaiss, Michael S ^b  

^a LIVER RESEARCH UNIT   (Mexico)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

allergic rhinitis; asthma; atopic dermatitis; house dust mite; immunotherapy; patient adherence; pollen; subcutaneous; sublingual; systemic reactions

Indexed keywords

ALLERGEN;

ALLERGEN IMMUNOTHERAPY; ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ATOPIC DERMATITIS; CLINICAL EFFECTIVENESS; HEALTH CARE COST; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; INTERMETHOD COMPARISON; MEDICAL HISTORY; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SELECTION; PRICK TEST; PROVOCATION TEST; REVIEW; SAFETY; SENSITIZATION; SKIN TEST; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT CONTRAINDICATION; ADVERSE EFFECTS; ECONOMICS; HYPERSENSITIVITY; IMMUNOLOGY; PATHOLOGY; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

ALLERGENS; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; SUBLINGUAL IMMUNOTHERAPY;

EID: 84907814791     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.55     Document Type: Review

References (100)

1. Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J. Allergy Clin. Immunol. 131(5), 1361-1366 (2013
2. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A metaanalysis- based comparison. J. Allergy Clin. Immunol. 130(5), 1097-1107 e2 (2012
3. Kiel MA, Roder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Molken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J. Allergy Clin. Immunol. 132(2), 353-360 e2 (2013
4. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I et al. Allergen immunotherapy: a practice parameter third update. J. Allergy Clin. Immunol. 127(1 Phase I), S1-S55 (2011
5. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergenspecific immunotherapy. Allergy 61(Phase I 82), 1-20 (2006
6. Canonica GW. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. (2010). http://www.allergychoices.com/school1000162/genie59/ images/files/sub-lingual-immunotherapy-world-allergy.11. pdf. [updated 19 jun 2010; cited 2010 19 june]
7. Murphy K, Gawchik S, Bernstein D, Andersen J, Rud Pedersen M. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. J. Negative Results Biomed. 12(1), 10 (2013
8. Larenas Linnemann D, Fogelbach GA, Cruz AA. Practice patterns in Mexican allergologists about skin tests with allergens during 2005-2006. Rev. Alerg. Mex. 55(1), 10-17 (2008
9. Larenas-Linnemann D, Cox LS. European allergen extract units and potency: review of available information. Ann. Allergy Asthma Immunol. 100(2), 137-145 (2008
10. Larenas-Linnemann D, Esch RE, Guidos-Fogelbach G, Rodriguez-Perez N. A comparison of in vitro potency between European and Mexican allergen extracts and US (CBER/FDA) reference extracts. Allergol. Immunopathol. (Madr). 38(4), 170-173 (2010
11. Larenas-Linnemann D, Cruz AA, Gutierrez IR, Rodriguez P, Shah-Hosseini K, Michels A et al. European and Mexican vs US diagnostic extracts of Bermuda grass and cat in skin testing. Ann. Allergy Asthma Immunol. 106(5), 421-428 (2011
12. Larenas-Linnemann D, Matta-Campos J, Shah K, Michels A, Moesges R. The biologic potency by skin prick testing (SPT) of a US diagnostic allergen extracts of Dermatophagoides pteronyssinus is two-fold higher compared with European and Mexican extracts. Allergy 64(s90), 16 (2009). Abstract
13. Larenas-Linnemann D, Matta JJ, Shah-Hosseini K, Michels A, Mosges R. Skin prick test evaluation of Dermatophagoides pteronyssinus diagnostic extracts from Europe, Mexico, and the United States. Ann. Allergy Asthma Immunol. 104(5), 420-425 (2010
14. Sander I, Fleischer C, Meurer U, Bruning T, Raulf-Heimsoth M. Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy (2009
15. Rossi R, Monasterolo G, Passalacqua G. The biological potency of different extracts for sublingual immunotherapy assessed by skin prick tests. Eur. Ann. Allergy Clin. Immunol. 42(3), 112-114 (2010
16. Lupinek C, Wollmann E, Baar A, Banerjee S, Breiteneder H, Broecker BM et al. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. Methods (2013
17. Rondon C, Campo P, Galindo L, Blanca-Lopez N, Cassinello MS, Rodriguez-Bada JL et al. Prevalence and clinical relevance of local allergic rhinitis. Allergy 67(10), 1282-1288 (2012
18. Bousquet J, Schunemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy 66(6), 765-774 (2011
19. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 318(7183), 593-596 (1999
20. Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 64(5), 669-677 (2009
21. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650), 924-926 (2008
22. Calderon MA, Larenas D, Kleine-Tebbe J, Jacobsen L, Passalacqua G, Eng PA et al. European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy'. Allergy (2011
23. Joint Task Force on Practice Parameters Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 90(1 Phase I 1), 1-40 (2003
24. J C. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates, Hillsdale, NJ (1988
25. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: cochrane systematic review and meta-Analysis. Clin. Exp. Allergy 41(9), 1263-1272 (2011
26. Ewan PW, Alexander MM, Snape C, Ind PW, Agrell B, Dreborg S. Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite. Clin. Allergy 18(5), 501-508 (1988
27. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin. Exp. Allergy 33(8), 1076-1082 (2003
28. Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy 47(3), 249-254 (1992
29. Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J. Allergy Clin. Immunol. 111(1), 155-161 (2003
30. Nanda A, O'Connor M, Anand M, Dreskin SC, Zhang L, Hines B et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J. Allergy Clin. Immunol. 114(6), 1339-1344 (2004
31. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin. Exp. Allergy 27(8), 860-867 (1997
32. Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Schou C et al. Long-Term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J. Allergy Clin. Immunol. 96(6 Pt 1), 879-885 (1995
33. Lent AM, Harbeck R, Strand M, Sills M, Schmidt K, Efaw B et al. Immunologic response to administration of standardized dog allergen extract at differing doses. J. Allergy Clin. Immunol. 118(6), 1249-1256 (2006
34. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-Analysis. Allergy 60(1), 4-12 (2005
35. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 66(6), 740-752 (2011
36. Larenas-Linnemann D. Certainties and doubts about sublingual and oral immunotherapy in children. Curr. Opin. Allergy Clin. Immunol. 9(6), 558-567 (2009
37. Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr. Opin. Allergy Clin. Immunol. 9(2), 168-176 (2009
38. Larenas-Linnemann D, Blaiss M, Van Bever HP, Compalati E, Baena-Cagnani CE. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Ann. Allergy Asthma Immunol. 110(6), 402-415 e9 (2013
39. Bergmann KC, Demoly P, Worm M, Fokkens WJ, Carrillo T, Tabar AI et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J. Allergy Clin. Immunol. (2013
40. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-Analysis. J. Allergy Clin. Immunol. 126(3), 558-566 (2010
41. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 62(8), 958-961 (2007
42. Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 53(7), 662-672 (1998
43. Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez- Cuervo C, Chelladurai Y et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 309(12), 1278-1288 (2013
44. Adkinson NF Jr, Eggleston PA, Eney D, Goldstein EO, Schuberth KC, Bacon JR et al. A controlled trial of immunotherapy for asthma in allergic children. N. Engl. J. Med. 336(5), 324-331 (1997
45. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. (4), CD001186. (2003
46. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 8, CD001186 (2010
47. Larenas-Linnemann DE, Pietropaolo-Cienfuegos DR, Calderon MA. Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. Ann. Allergy Asthma Immunol. 107(5), 407-416 e11 (2011
48. Kim JM, Lin SY, Suarez-Cuervo C, Chelladurai Y, Ramanathan M, Segal JB et al. Allergen specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics 131(6), 1155-1167 (2013
49. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 133(3), 599-609 (2008
50. Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 61(10), 1177-1183 (2006
51. Charpin D, Gouitaa M, Dron-Gonzalvez M, Fardeau MF, Massabie-Bouchat YP, Hugues B et al. Immunotherapy with an aluminum hydroxide-Adsorbed Juniperus ashei foreign pollen extract in seasonal indigenous cypress pollen rhinoconjunctivitis. A double-blind, placebo-controlled study. Int. Arch. Allergy Immunol. 143(2), 83-91 (2007
52. Mahdy RA, Nada WM, Marei AA. Subcutaneous allergenspecific immunotherapy versus topical treatment in vernal keratoconjunctivitis. Cornea 31(5), 525-528 (2012
53. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-Analysis of randomized controlled trials. J. Allergy Clin. Immunol. 132(1), 110-117 (2013
54. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F et al. Sublingual immunotherapy in mitesensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 120(1), 164-170 (2007
55. Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J. Allergy Clin. Immunol. 116(2), 377-383 (2005
56. Bousquet PJ, Castelli C, Daures JP, Heinrich J, Hooper R, Sunyer J et al. Assessment of allergen sensitization in a general population-based survey (European Community Respiratory Health Survey I). Ann. Epidemiol. 20(11), 797-803 (2010
57. Craig TJ, King TS, Lemanske RF Jr, Wechsler ME, Icitovic N, Zimmerman RR Jr et al. Aeroallergen sensitization correlates with PC(20) and exhaled nitric oxide in subjects with mild-To-moderate asthma. J. Allergy Clin. Immunol. 121(3), 671-677 (2008
58. Larenas-Linnemann DE, Fogelbach GA, Alatorre AM, Cruz AA, Colin DD, Pech JA et al. Patterns of skin prick test positivity in allergic patients: usefulness of a nationwide SPT chart review. Allergol. Immunopathol. (Madr). 39(6), 330-336 (2011
59. Larenas Linnemann D, Guidos Fogelbach GA, Arias Cruz A. [Practice patterns in Mexican allergologists about specific immunotherapy with allergens]. Rev. Alerg. Mex. 55(2), 53-61 (2008
60. Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin. Exp. Allergy 39(3), 387-393 (2009
61. Johnstone DE, Crump L. Value of hyposensitization therapy for perennial bronchial asthma in children. Pediatrics 27, 39-44 (1961
62. Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injecton therapy in ragweed hay fever. N. Engl. J. Med. 273(13), 675-679 (1965
63. Franklin W, Lowell FC. Comparison of two dosages of ragweed extract in the treatment of pollenosis. JAMA 201(12), 915-917 (1967
64. Marogna M, Spadolini I, Massolo A, Zanon P, Berra D, Chiodini E et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann. Allergy Asthma Immunol. 98(3), 274-280 (2007
65. Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J. Allergy Clin. Immunol. 130(1), 215-224 e7 (2012
66. Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J. Allergy Clin. Immunol. 124(1), 150-156 e1-e5 (2009
67. Emminger W, Durham S, Riis B, Maloney J, Nolte H. The Efficacy Of Single-grass-Allergen-immunotherapy-Tablet Treatment In Mono- And Multi-sensitized Allergic Rhinitis Patients: Findings From A Post Hoc Analysis. J. Allergy Clin. Immunol. 123(2), S75 (2009
68. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59(1), 45-53 (2004
69. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebocontrolled, double-blind, double-dummy study. Int. Arch. Allergy Immunol. 157(3), 288-298 (2012
70. Keles S, Karakoc-Aydiner E, Ozen A, Izgi AG, Tevetoglu A, Akkoc T et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J. Allergy Clin. Immunol. 128(4), 808-815 e7 (2011
71. Calderon MA, Eichel A, Makatsori M, Pfaar O. Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. Curr. Opin. Allergy Clin. Immunol. 12(3), 249-256 (2012
72. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma &Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J. Allergy Clin. Immunol. 131(5), 1288-1296 e3 (2013
73. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A et al. Specific immunotherapy has long-Term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62(8), 943-948 (2007
74. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J. Allergy Clin. Immunol. 126(5), 969-975 (2010
75. Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco AD et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann. Allergy Asthma Immunol. 101(2), 206-211 (2008
76. Didier A, Malling HJ, Worm M, Horak F, Sussman G, Melac M et al. Post-Treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin. Exp. Allergy 43(5), 568-577 (2013
77. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J. Allergy Clin. Immunol. 129(3), 717-725 e5 (2012
78. Vovolis V, Kalogiros L, Mitsias D, Sifnaios E. Severe repeated anaphylactic reactions to sublingual immunotherapy. Allergol. Immunopathol. (Madr). 41(4), 279-281 (2013
79. Vitaliti G, Pavone P, Guglielmo F, Falsaperla R. Sublingual immunotherapy in preschool children: an update. Expert Rev. Clin. Immunol. 9(4), 385-390 (2013
80. Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann. Allergy Asthma Immunol. 95(3), 254-258 (2005
81. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin. Exp. Allergy 35(5), 560-564 (2005
82. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 61(2), 181-184 (2006
83. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 64(6), 963-964 (2009
84. Larenas Linnemann D, Hauswirth D, Calabria C, Sher L, Rank M. AAAAI Survey On Allergen Immunotherapy (AIT) In Patients With Specific Medical Conditions. J. Allergy Clin. Immunol. 131(2 Phase I), AB229 (2013
85. Rank M, Calabria C, Hauswirth D, Sher L, Larenas Linnemann D. AAAAI Membership Experience with Allergen Immunotherapy (AIT) Safety in Young Children and Pregnant Women. J. Allergy Clin. Immunol. 131(2 Phase I), AB186 (2013
86. Bengoa R. Adherence to long-Term Therapies, evidence for action: WHO; 2003 [cited 2014 2nd of February]. www.who.int/chp/knowledge/publications/adherence-report/en/.
87. Blaiss M, Dykewicz M, Skoner DP. Diagnosis and Treatment of Nasal and Ocular Allergies: The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) Surveys. Ann. Allergy Asthma Immunol. 112(4), 322-328 (2014
88. Guenechea-Sola M, Hariri SR, Galoosian A, Yusin JS. A retrospective review of veterans' adherence to allergen immunotherapy over 10 years. Ann. Allergy Asthma Immunol. 112(1), 79-81 (2014
89. Pajno GB, Caminiti L, Crisafulli G, Barberi S, Landi M, Aversa T et al. Adherence to sublingual immunotherapy in preschool children. Pediatr. Allergy Immunol. 23(7), 688-689 (2012
90. Anolik R, Schwartz A, Sajjan S, Allen-Ramey F. Persistence with Specific Immunotherapy (SCIT &SLIT) Among AR Patients in A US Allergy Practice. J. Allergy Clin. Immunol. 131(2, Phase I), AB186 (2013
91. Hankin CS, Cox L, Lang D, Levin A, Gross G, Eavy G et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J. Allergy Clin. Immunol. 121(1), 227-232 (2008
92. Gonzalez-de-Olano D, Alvarez-Twose I. Adherence to immunotherapy in times of financial crisis. Ann. Allergy Asthma Immunol. 110(6), 466-468 (2013
93. Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 63(12), 1624-1629 (2008
94. Bruggenjurgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann. Allergy Asthma Immunol. 101(3), 316-324 (2008
95. Ruggeri M, Oradei M, Frati F, Puccinelli P, Romao C, Dell'Albani I et al. Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults. Clin. Drug Invest. 33(5), 343-349 (2013
96. Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. J. Allergy Clin. Immunol. 131(4), 1084-1091 (2013
97. Reinhold T, Ostermann J, Thum-Oltmer S, Bruggenjurgen B. Influence of subcutaneous specific immunotherapy on Drug costs in children suffering from allergic asthma. Clinical and translational Allergy 3(1), 30 (2013
98. Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Ann. Allergy Asthma Immunol. 100(5), 482-489 (2008
99. Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin. Exp. Allergy 43(1), 22-28 (2013
100. Shaikh WA, Shaikh SW. A prospective study on the safety of sublingual immunotherapy in pregnancy. Allergy 67(6), 741-743 (2012